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Atherosclerosis is often associated with chronic vascular inﬂammation.  High-mobility group box 1 
protein (HMGB1) plays various roles,  not only as a transcriptional regulatory factor in the nucleus,  
but also as an inﬂammatory mediator.  A previous study suggested that ﬁbrinogen is an important fac-
tor associated with atherosclerosis progression.  The present study was performed to examine the 
levels of plasma HMGB1 protein in atherosclerosis patients.  We studied 24 patients with peripheral 
artery disease (PAD) with atherosclerosis,  and 10 healthy controls.  We found that the concentrations 
of HMGB1 were increased in the plasma of the patients with atherosclerosis,  and there were signiﬁ-
cant correlations between the plasma HMGB1 and ﬁbrinogen levels.  Plasma HMGB1 may play a key 
role in the pathogenesis of clinical and experimental atherosclerosis.
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therosclerosis is the one of the most common 
causes of cardiovascular disease.  Although 
atherosclerosis is associated with hypertension,  dia-
betes and hyperlipidemia,  recent studies suggest an 
additional association with inﬂammation and the 
coagulation system.
　 High-mobility group box 1 protein (HMGB1) is a 
nuclear protein present in many cells.  When inﬂamma-
tion occurs,  HMGB1 is released into the extracellular 
space in both an active and a passive manner.  It func-
tions as a signal for inducing inﬂammation and as an 
activator for inducing the immune response [1,  2].  
The action of extracellular HMGB1 appears to be 
dependent on its interactions with several cell surface 
receptors,  e.g.,  the receptor for advanced glycation 
end products (RAGE) and toll-like receptor 2/4 
(TLR-2/4).  Extracellular HMGB1 has been reported 
in a variety of clinical conditions associated with 
inﬂammation and reperfusion injury [3-6].
　 Itʼs was suggested that atherosclerosis is charac-
terized by a chronic inﬂammatory response to arterial 
wall injury [7].  RAGE is expressed in human athero-
sclerotic lesions [8].  Smooth muscle cells with ath-
erosclerosis show increased expressions of HMGB1 
and RAGE [9,  10].  RAGE expression is signiﬁcantly 
up-regulated in macrophages associated with athero-
sclerotic lesions [8],  and inhibition of RAGE signal-
ing prevents the progression of atherosclerotic injury 
[11].
　 In the coagulation system,  serum ﬁbrinogen is one 
of the factors associated with blood coagulation and 
viscosity.  Fibrinogen may therefore be closely related 
to atherosclerosis [8-10].  It was suggested that the 
mortality rate of individuals with cardiovascular dis-
ease is associated with high levels of serum ﬁbrinogen 
[12].  Fibrinogen is essential for ﬁbrin formation 
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under the inﬂuence of thrombin and platelet aggrega-
tion [13].  In addition,  ﬁbrinogen synthesis is stimu-
lated by cytokines from activated macrophages,  and 
thus ﬁbrinoge behaves as an acute-phase protein [14].
　 These observations suggest that ﬁbrinogen,  like 
HMGB1,  might be associated with the coagulation and 
inﬂammation systems.  In the present stud,  we exam-
ined the expression of plasma HMGB1 in patients with 
atherosclerosis and we evaluated the correlation 
between plasma HMGB1 and the inﬂammatory or 
coagulation systems.
Materials and methods
　 The plasma levels of HMGB1 were measured in 10 
healthy controls (age 66.3±11.7 years,  7 males and 3 
females) and 24 PAD patients (age 64.5±17.4 years,  
21 males and 3 females).  All patients and volunteers 
provided informed consent,  and the study was approved 
by the institutional review board at Okayama University 
Hospital (Okayama,  Japan).  First blood samples 
(0.5mL) were collected from the subjectsʼ peripheral 
vein and then centrifuged (3,000rpm,  10min) to obtain 
plasma samples.  Second blood samples (0.5mL) were 
collected using citric acid and centrifuged to obtain 
plasma samples.  After centrifugation,  these samples 
were stored at －80℃ until they were analyzed.  The 
last blood samples (0.5mL) were collected using EDTA 
2Na for the blood cell counts.
　 The concentration of HMGB1 in plasma samples 
was determined using an enzyme-linked immunosor-
bent assay (ELISA) kit according to the manufac-
turerʼs protocol (Shino-Test,  Sagamihara,  Japan).  
The HMGB1 levels are expressed as nanograms per 
milliliter (ng/mL).  We then analyzed the white blood 
cells count (WBC: ×104/mm2),  C-reactive protein 
(CRP: mg/dL),  platelet count (Plt: ×104/mm2),  
activated partial thromboplastin time (APTT: sec),  
and ﬁbrinogen (Fib: mg/dL) using the standard meth-
ods established by the Department of the Central 
Clinical Laboratory,  Okayama University Hospital.
　 The patients were divided into 2 groups according 
to the ankle brachial pressure index (ABI): the mild 
PAD group (ABIｧ0.6) and the severe PAD group 
(ABI＜0.6).  All data are expressed as the mean ± 
SD.  Group comparisons were performed using an 
analysis of variance (ANOVA) followed by the Mann-
Whitney U-test.  Correlation coeﬃcients were deter-
mined using the Spearman rank test.  In order to 
identify possible confounders of the correlation 
between HMGB1 and PAD both a univariate and a 
multivariate analysis with a multiple linear regression 
model were performed.  A probability of ＜0.05 was 
considered to be signiﬁcant.
Results
　 HMGB1 expression in systemic circulation.
The patients with PAD showed higher plasma levels 
of HMGB1 compared to the healthy controls (n＝10,  
median 4.63ng/mL; 95ｵ conﬁdence interval [CI] 
3.56-5.41).  In addition,  there were signiﬁcant diﬀer-
ences in the plasma HMGB1 levels between the mild 
(n＝12,  median 6.16 (3.51-11.25; 95ｵ CI) ng/mL;  
p＜0.05 vs. severe PAD group) and severe PAD 
patients (n＝12,  median 16.18ng/mL; 95ｵ CI 3.18-
29.00; p＜0.01 vs.  control group) (Fig.  1).
　 Relationship between plasma HMGB1 and 
inﬂammatory or coagulation factors. The 
demographic data for the 24 subjects are presented in 
Table 1.  The PAD grade also showed a signiﬁcant 
correlation with the plasma level of ﬁbrinogen (438±
99mg/dL in the mild PAD group vs. 559±151mg/
dL in the severe PAD group; p＜0.05). Table 2 shows 
the results of the multivariable analysis for factors 
correlated with plasma HMGB1 levels.  Both the ABI 
(p＝0.003) and the plasma level of ﬁbrinogen (p＜
0.001) were signiﬁcantly associated with the subjectsʼ 
HMGB1 levels.  However,  CRP and other coagula-























Fig. 1　 The plasma levels of HMGB1 in atherosclerosis patients 
and relations between atherosclerosis progress and plasma levels of 
HMGB1.  Data represent the median ±95% conﬁdence interval 
(CI).  ＊p＜ .05,  ＊＊p＜ .01 in comparison to the severe PAD group.  
PAD; peripheral artery disease.
tion-related factors demonstrated no signiﬁcant rela-
tionship with HMGB1.
　 Fig.  2 shows the relationships between the plasma 
HMGB1 and ﬁbrinogen levels.  The correlation coef-
ﬁcient was 0.455.  Table 3 shows the results of the 
multivariable analysis for factors correlated with 
plasma HMGB1 levels.  The only factor signiﬁcantly 
associated with the HMGB1 level was ﬁbrinogen 
(p＝ .003).  The multiple stepwise regression analysis 
showed that ﬁbrinogen was the only factor indepen-
dently related to the HMGB1 levels (R2＝0.353) 
(Table 4).
Discussion
　 Atherosclerosis and extracellular HMGB1.
Our results showed an association between athero-
sclerosis and increased plasma HMGB1 levels.  
Plasma HMGB1 levels have been reported to increase 
during inﬂammation,  such as sepsis [1] and lung 
inﬂammation [3].  In the present study,  the plasma 
HMGB1 levels in patients with PAD were much 
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(n＝12 ) p value
Male 9 (75.0) 12 (100.0)
Age,  years 63.9±15.9 65.1±18.0 0.869
Body weight,  kg 63.3±13.1 59.6±12.2 0.504
Systoric BP,  mmHg 145.4±16.2 134.2±12.4 0.109
Diastolic BP,  mmHg 77.1±8.0 77.6±6.7 0.880
Ambulatory distance,  m 174.3±294.4 34.5±30.2 0.116
ABI 0.72±0.10 0.32±0.15 ＜.001
Smoking 12 (100.0) 11 91.6
Medication for
　Hypertention 11 (91.6) 7 (83.3)
　Diabetes 7 (58.3) 3 (25.0)
　Hyperlipidemia 7 (58.3) 8 (32.0)
Laboratory values
WBC,  ×104/mm2 6,536±3,576 8,583±3,623 0.209
Hb,  mg/dl 12.1±2.4 12.8±2.4 0.509
Hct,  % 36.6±6.8 38.3±6.6 0.556
Plt,  ×104/mm2 22.2±7.2 34.4±19.7 0.078
APTT,  sec 32.9±4.8 31.8±6.7 0.657
Fibrinogen,  mg/dl 438±99 559±151 0.045
CRP,  mg/dl 1.25±2.13 1.38±3.00 0.912
HMGB1,  ng/ml 7.38±6.09 19.08±15.59 0.024
Data are expressed as mean ± SD or number (percentage).
PAD,  peripheral artery disease; BP,  blood pressure; ABI,  ankle brachial pressure index; WBC,  white blood cell number; Hb,  
hemoglobin; Hct; Plt,  platelet number; PT,  prothorombin time; APTT,  active partial thromboplastin time; CRP,  C-reactive protein.
Table 2　 Correlation coeﬃcients for HMGB1 in PAD patients
Variables Correlation coeﬃcients p value
Age,  years －0.022 0.922
Body weight,  kg  0.170 0.225
Systoric BP,  mmHg －0.288 0.231
Diastolic BP,  mmHg －0.301 0.210
Ambulatory distance, m －0.194 0.353
ABI －0.566 0.003






　WBC,  ×104/mm2  0.097 0.677
　Hb,  mg/dl  0.127 0.584
　Hct,  %  0.093 0.688
　Plt,  ×104/mm2  0.359 0.110
　APTT,  sec  0.211 0.371
　Fibrinogen,  mg/dl  0.754 ＜0.001
　CRP,  mg/dl  0.229 0.331
PAD,  peripheral artery disease; WBC,  white blood cell number;  
APTT,  active partial thromboplast; CRP,  C-reactive protein.
higher than those in healthy controls (Table 1).  The 
source of circulating HMGB1 in atherosclerosis 
patients has not been determined,  but 2 mechanisms 
are speculated to increase the general circulating 
HMGB1 levels.  A local inﬂammatory secretory release 
of HMGB1 might be induced from immune responder 
cells such as monocytes,  macrophages and endothelial 
cells with cytokine stimulation.  Atherosclerotic lesions 
express high levels of HMGB1,  thus leading to inﬂam-
mation in atherosclerotic lesions [1,  2,  9].  However,  
the source of plasma HMGB1 may be not only immune 
responder cells but also vascular smooth muscle cells 
in atherosclerotic plaques [10].
　 In atherosclerotic plaques,  endothelial cells and 
smooth muscle cells contain cytoplasmic HMGB1.  
HMGB1 is accumulated from the cytoplasm into 
secretory vesicles.  However,  atherosclerotic plaques 
contain extracellular HMGB1,  which is released from 
necrotic cells [9].  While atherosclerotic inﬂammation 
continues,  HMGB1 may be released into circulating 
blood.
　 It was suggested that HMGB1 is associated with 
the inﬂammatory and coagulation systems [15].  During 
the last stage of atherosclerosis,  plaque rupture 
induces the formation of a thrombus.  Endothelial cells 
lose their anti-coagulation properties and adhere to 
platelets.  As shown in Fig.  1,  the plasma levels of 
HMGB1 correlate with the progression of atheroscle-
rosis.  Normally,  patients with severe PAD have 
severe local infection and gangrene of the foot.  
However,  our present ﬁndings indicate that the 
infection-related factors WBC and CRP were not 
signiﬁcantly related to the ABI degree,  and thus the 
plasma level of HMGB1 may be independent from local 
infection or necrosis.  Therefore,  the extracellular 
HMGB1 secreted from atherosclerotic lesions and 
local HMGB1 may contribute platelets to the forma-
tion of thrombosis and the progression of atheroscle-
rosis.
　 Atherosclerosis and ﬁbrinogen. Athero-
sclerosis has been demonstrated to be associated with 
inﬂammatory processes in the vascular walls [15,  16].  
The activity and progression of atherosclerosis is 
inﬂuenced by vascular inﬂammation [17].  Fibrinogen 
is an acute protein marker as well as a coagulation 
factor and has various other functions such as deter-
mining the blood viscosity and stimulating vascular 
smooth muscle cell migration and proliferation.  
Fibrinogen provides an indirect measure of cytokine-
dependent inﬂammatory processes in the atheroscle-
rotic wall.  In addition to its role as a nonspeciﬁc 
marker of inﬂammation,  ﬁbrinogen is involved in 
atherogenesis and thrombogenesis by acting as a 
bridging molecule for many types of cell-to cell adhe-
sion events that are critical for atherogenesis [18].
　 Fibrinogen plays a central role in the coagulation 
cascade and has a critical impact on the formation of 
ﬁbrin clots following the rupture of an atherosclerotic 
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Table 3　 Multivariable analysis for correlates of HMGB1 levels
Characteristics β SE p
ABI －0.563 10.118 0.310
WBC  0.201 0.774 0.455
Hb －0.133 4.412 0.892
Plt －0.474 0.019 0.100
APTT  1.843 2.758 0.056
Fibrinogen  0.783 0.021 0.003
CRP －1.400 3.006 0.065
Table 4　 Multiple stepwise regression analysis for correlate of 
plasma HMGB1
Characteristics β SE p


























Fig. 2　 The scatterplot shows that the relations between Plasma 
HMGB1 levels and ﬁbrinogen for healthy control and peripheral 
artery disease.  r,  correlation coeﬃcient.
plaque [19].  The agents used to treat atherosclero-
sis,  such as statins and angiotensin-converting enzyme 
inhibitors,  which improve clinical outcomes in primary 
and secondary prevention [20],  decrease the ﬁbrino-
gen levels [21].  It was thus suggested that increased 
plasma ﬁbrinogen is one of the risk factors for PAD 
[8-10].  In the present study,  there was a signiﬁcant 
correlation between HMGB1 and ﬁbrinogen (Fig.  2).
　 In addition,  the present subjectsʼ ﬁbrinogen levels 
were independently correlated with HMGB1 levels 
(Table 3).  The multiple stepwise regression analysis 
showed that ﬁbrinogenʼs R2 (multiple regression coef-
ﬁcient) was 0.353,  and the p-value for ﬁbrinogen was 
0.006 (Table 4).  Our results may indicate a causal 
relationship between HMGB1 and ﬁbrinogen,  and thus,  
high levels of plasma HMGB1 and ﬁbrinogen may 
induce atherosclerotic progression.  A prior study 
suggested that HMGB1 is a potential biomarker for 
subclinical inﬂammation [1].  HMGB1 may be a good 
candidate as a marker for atherosclerosis.
　 Here we found that the concentration of HMGB1 
was increased in the patients with atherosclerosis,  and 
the level of plasma HMGB1 was correlated with that 
of ﬁbrinogen.  We therefore speculate that the plasma 
HMGB1 level is increased in atherosclerotic patients,  
and a signiﬁcant correlation between the plasma 
HMGB1 and plasma ﬁbrinogen levels will be examined 
and perhaps conﬁrmed in future studies.
　 However,  our study also has some technical limita-
tions.  First,  we evaluated a very small number of 
patients.  Comparisons of large numbers of PAD 
patients may better elucidate the relationships among 
plasma HMGB1,  ﬁbrinogen and PAD.  Second,  we 
used only the ABI for our atherosclerosis classiﬁca-
tion.  The ABI values were obtained with an oscillo-
metric automated device,  and small diﬀerences in the 
deviceʼs measurements may have altered the ﬁnal 
numerical ABI values.  Using another measurement 
device such as a skin perfusion pressure (SPP) or 
transcutaneous partial pressure (tcPO2) device may 
better clarify these relations.  Third,  we do not yet 
know the mechanisms underlying how HMGB1 is 
related to atherosclerosis.  A longitudinal study is 
needed to clarify the causal relationships among 
HMGB1,  ﬁbrinogen levels,  and atherosclerosis pro-
gression.  We also do not know whether HMGB1 as a 
biomarker has a strong relationship with atheroscle-
rosis progression.  Further investigations of the role 
of HMGB1 may make it possible to identify a novel 
biomarker for atherosclerosis.
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